The clinical impact of switching attention deficit hyperactivity disorder patients from OROS®-MPH to Novo-MPH ER-C®: A paediatric practice review
Open Access
- 1 February 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 18 (2) , 70-73
Abstract
In Canada, novo-methylphenidate extended-release capsules (Novo-MPH ER-C, Novopharm Limited, Canada) was approved as being bioequivalent to a current first-line treatment for attention deficit hyperactivity disorder (ADHD), CONCERTA (OROS-MPH, Janssen Inc, Canada). The present practice review was undertaken to determine whether bioequivalence of these products translates into therapeutic equivalence. The present study was a retrospective, single-centre, observational review of consecutive paediatric ADHD patients prescribed OROS-MPH during a seven-month period. Of the 53 patients who had been switched to the bioequivalent product, 87% destabilized and 43% indicated a shorter duration of effect. In comparison, of those who never tried the second entry medication, only 26% destabilized. Qualitative data indicated differences with regard to side effects, efficacy and duration of effect. The present retrospective study indicated that Novo-MPH ER-C is not therapeutically equivalent to OROS-MPH. Once an individual with ADHD is effectively managed, disruption of their treatment should be avoided.Keywords
This publication has 17 references indexed in Scilit:
- Differences in the In Vitro and In Vivo Pharmacokinetic Profiles of Once-Daily Modified-Release Methylphenidate Formulations in Canada: Examination of Current Bioequivalence CriteriaClinical Therapeutics, 2012
- Lack of bioequivalence between two methylphenidate extended modified release formulations in healthy volunteersInt. Journal of Clinical Pharmacology and Therapeutics, 2009
- Effectiveness, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Optimization StudyJournal of Child and Adolescent Psychopharmacology, 2009
- Development of a New Once-a-Day Formulation of Methylphenidate for the Treatment of Attention-deficit/Hyperactivity DisorderArchives of General Psychiatry, 2003
- Methylphenidate bioavailability from two extended-release formulationsInt. Journal of Clinical Pharmacology and Therapeutics, 2002
- Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder.2001
- A 14-Month Randomized Clinical Trial of Treatment Strategies for Attention-Deficit/Hyperactivity DisorderArchives of General Psychiatry, 1999
- Evidence-based pharmacotherapy for attention-deficit hyperactivity disorderInternational Journal of Neuropsychopharmacology, 1999
- A Prospective Study of Hyperactive Boys With Conduct Problems and Normal Boys: Adolescent and Adult CriminalityJournal of the American Academy of Child & Adolescent Psychiatry, 1997
- Anger control in response to verbal provocation: Effects of stimulant medication for boys with ADHDJournal of Abnormal Child Psychology, 1989